TruScreen targets FY26 cash flow positive with sales growth

TruScreen Group Ltd projects FY26 sales to exceed NZ$2.8m, a 64% year-over-year increase from FY25 actual sales of NZ$1.71m. This growth is anticipated to make the company monthly cash flow positive by March 2026. Revenue diversification includes contributions from new distributors in Indonesia and India, public screening programs, and a strategic alliance with Dalton Bio for HPV DNA equipment and kits.

Public screening programs are forecast to contribute over 20% of total sales in FY26, a notable increase from 99% of FY25 sales coming from traditional channels. Key programs include a 5-year, 260,000-women screening program in Ho Chi Minh City, Vietnam, launching in July 2025, and a re-validated program in Zimbabwe targeting 20,000 women in FY26. Uzbekistan also plans a 500-patient pilot project in September/October.

China remains TruScreen’s largest market, though reliance on China sales is projected to decrease by approximately 30% from 87% in FY25 to 62.5% in FY26. The company is also expanding its product portfolio through a partnership with Dalton Hangzhou Bio Science to distribute HPV testing products.